Opportunity

CanadaBuys #W6369-27-A089

DND procurement of POLYSERP MENA and POLYSERP PAN-AFRICA snake antivenoms

Posted

November 20, 2026

Respond By

December 05, 2026

Identifier

W6369-27-A089

NAICS

325414

Canada’s Department of National Defence is seeking two broad-spectrum polyvalent antivenoms for Canadian Armed Forces medical use. - Government buyer: Department of National Defence (DND), through the Strategic Medical Countermeasures Program, for the Canadian Armed Forces Health Services Group; the notice identifies National Defence Headquarters and the Assistant Deputy Minister (Materiel). - Named supplier/OEM: CRO, LLC is the pre-identified supplier and the only supplier currently known to meet the requirement. This is an Advance Contract Award Notice, not an award; other capable suppliers may submit a Statement of Capabilities. - Products and quantities: - POLYSERP MENA: 36 vials per scheduled delivery across three deliveries (108 scheduled), plus an option for up to 72 additional vials; 180 vials maximum potential quantity. - POLYSERP PAN-AFRICA: 36 vials per scheduled delivery across three deliveries (108 scheduled), plus an option for up to 72 additional vials; 180 vials maximum potential quantity. - Use and coverage: Treat cytotoxic, hemotoxic, and neurotoxic snake envenomation. POLYSERP MENA is described as covering 27 Viperidae and Elapidae species across North Africa and the Middle East; PAN-AFRICA is intended for broad coverage in Sub-Saharan Africa. - Key product requirements: Sterile, non-pyrogenic lyophilized powder for reconstitution and intravenous administration; at least 36 months’ shelf life; approved indications, documented species coverage, and applicable regulatory and quality documentation. - Alternatives noted: INOSERP MOAN/MENA and Saudi AVPC/NAVPC polyvalent antivenom are cited as comparable products, but the notice says they do not provide equivalent breadth of species and geographic coverage. - Potential value: CAD 433,475 including options and applicable taxes.

Description

The Department of National Defence requires POLYSERP MENA and POLYSERP PAN-AFRICA snake antivenoms to treat cytotoxic, hemotoxic, and neurotoxic snakebite syndromes. The requirement includes initial delivery of 36 vials of each product by 31 March 2027, additional scheduled deliveries in fiscal years 2028–2029 and 2030–2031, and options for up to 72 additional vials of each product. The proposed contract is estimated to run from award through 31 March 2031. This Advance Contract Award Notice identifies CRO, LLC as the only supplier currently known to meet the requirements and invites capable suppliers to submit a Statement of Capabilities.

View original listing